Choi Young Hee
College of Pharmacy and Integrated Research Institute for Drug Development, Dongguk University_Seoul, 32 Dongguk-lo, Ilsandong-gu, Goyang-si, Gyeonggi-do 10326, Korea.
Pharmaceutics. 2020 May 2;12(5):417. doi: 10.3390/pharmaceutics12050417.
Systemic exposure of a drug is generally associated with its pharmacodynamic (PD) effect (e.g., efficacy and toxicity). In this regard, the change in area under the plasma concentration-time curve (AUC) of a drug, representing its systemic exposure, has been mainly considered in evaluation of drug-drug interactions (DDIs). Besides the systemic exposure, the drug concentration in the tissues has emerged as a factor to alter the PD effects. In this review, the status of systemic exposure, and/or tissue exposure changes in DDIs, were discussed based on the recent reports dealing with transporters and/or metabolic enzymes mediating DDIs. Particularly, the tissue concentration in the intestine, liver and kidney were referred to as important factors of PK-based DDIs.
药物的全身暴露通常与其药效学(PD)效应(如疗效和毒性)相关。在这方面,代表药物全身暴露的血浆浓度-时间曲线下面积(AUC)的变化在药物相互作用(DDIs)评估中一直被主要考虑。除了全身暴露外,组织中的药物浓度已成为改变PD效应的一个因素。在本综述中,基于近期涉及介导DDIs的转运体和/或代谢酶的报道,讨论了DDIs中全身暴露和/或组织暴露变化的情况。特别是,肠道、肝脏和肾脏中的组织浓度被认为是基于药代动力学的DDIs的重要因素。